The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis. (PubMed, Cancer Med) - Nov 15, 2024 - "FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second-line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort."
Clinical • Journal • Retrospective data • Review • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1
|
|
Eun Taeg Kim; Eun Young Park; Han Song Park; In Hye Song; Ji Hyun Kim; Myong Cheol Lim; Sang-Yoon Park
|